Welcome to our dedicated page for Savara news (Ticker: SVRA), a resource for investors and traders seeking the latest updates and insights on Savara stock.
Savara Inc. (symbol: SVRA) is a specialty biopharmaceutical company that focuses on developing innovative therapies for rare respiratory diseases. The company’s principal approach centers on addressing serious and life-threatening pulmonary conditions. Its flagship product, AeroVanc, is the first-ever dry powder inhaled antibiotic specifically designed to treat methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis (CF). This groundbreaking treatment aims to improve the quality of life and health outcomes for these patients.
Another significant project by Savara is the molgramostim nebulizer solution (molgramostim). This is an inhaled granulocyte-macrophage colony-stimulating factor currently in Phase 3 development for treating autoimmune pulmonary alveolar proteinosis (aPAP). aPAP is a rare and often debilitating lung disease with limited treatment options, and molgramostim seeks to fill this critical gap.
Savara's dedication to addressing unmet medical needs is evident through its focused development pipeline. The company operates as a single-segment entity specializing in respiratory system pharmaceuticals, highlighting its concentrated expertise and commitment to improving respiratory health.
In terms of financial health and partnerships, Savara has made strategic moves to secure funding and collaborations that bolster its research and development efforts. These partnerships and financial strategies are crucial for advancing its clinical programs and bringing innovative treatments to market.
For more detailed information on the company and its projects, please visit Savara’s official websites at www.savarapharma.com and www.aerovanc.com.
Savara Inc. (Nasdaq: SVRA) has initiated a rolling submission of a Biologics License Application (BLA) to the FDA for MOLBREEVI, targeting the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease. The company expects to complete the BLA submission by the end of Q1 2025 and will request priority review.
MOLBREEVI has received multiple regulatory designations including Fast Track, Breakthrough Therapy, and Orphan Drug Designation from both FDA and EMA. The drug demonstrated positive results in the Phase 3 IMPALA-2 trial, showing a favorable benefit-risk profile. If approved, MOLBREEVI would be the first approved treatment for aPAP in the U.S. and Europe.
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's Chair and CEO, Matt Pauls, will present on January 15 at 5:15pm PT/8:15pm ET at the Westin St. Francis in San Francisco. The presentation will be available via live webcast and will remain accessible for 30 days on the company's website.
Savara announced the grant of inducement awards to four new employees on November 20, 2024. The awards include options to purchase 80,000 shares of common stock and restricted stock units (RSUs) covering 70,000 shares. The options have an exercise price of $3.13 per share, with a 10-year term and quarterly vesting over four years. The RSUs vest fully after two years. These equity awards were granted under Savara's 2021 Inducement Equity Incentive Plan in accordance with NASDAQ Listing Rules.
Savara announced an encore presentation of Phase 3 IMPALA-2 trial results for Molgramostim inhalation solution in patients with autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the upcoming British Thoracic Society Winter Meeting 2024. The presentation titled 'Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Related Quality of Life in Patients with aPAP' will be delivered by Dr. Cormac McCarthy on November 29, 2024, in London. The presentation will showcase how the treatment improves pulmonary gas exchange and respiratory health-related quality of life in aPAP patients.
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced its participation in two major healthcare conferences. The company will participate in fireside chats at the Jefferies London Healthcare Conference (November 19-21, 2024) and the Piper Sandler 36th Annual Healthcare Conference (December 3-5, 2024).
The fireside chats are scheduled for November 20th at 1:00pm GT/8:00am ET and December 3rd at 8:30am ET respectively. Live webcasts and replays will be accessible through Savara's corporate website and will remain available for 90 days.
Savara Inc. (SVRA) reported Q3 2024 financial results and business updates. The company plans to initiate a rolling BLA submission for MOLBREEVI by year-end, with completion expected by end of Q1 2025. The company reported a net loss of $24.2 million ($0.11 per share) compared to $16.6 million in Q3 2023. R&D expenses increased 46.5% to $20.3 million, while G&A expenses rose 45% to $6.0 million. With approximately $219.4 million in cash and short-term investments, Savara believes it is capitalized through Q2 2027.
Savara (Nasdaq: SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced its participation in the Guggenheim Inaugural Healthcare Conference. The company's management team will engage in a fireside chat scheduled for November 12, 2024, at 10:00am PT/1:00pm ET.
The event will be accessible through a live webcast on Savara's website, with the recording remaining available for 90 days following the presentation.
Savara Inc. (Nasdaq: SVRA) announced that a new episode of The Balancing Act® on Lifetime TV's Behind the Mystery™ series is featuring autoimmune Pulmonary Alveolar Proteinosis (aPAP). The episode, sponsored by Savara, focuses on an aPAP patient's diagnostic journey and includes insights from Dr. Bruce Trapnell, the International Coordinating Investigator for Savara's IMPALA-2 Phase 3 clinical trial of molgramostim inhalation solution in aPAP.
The episode aims to educate viewers about aPAP's symptoms and diagnosis, highlighting the lack of approved treatments in the US and Europe. Savara's CEO, Matt Pauls, emphasized the company's commitment to the aPAP community and their goal of providing an effective therapy. Savara expects to complete submission of the Biologics License Application (BLA) for molgramostim in aPAP with the FDA in the first half of 2025.
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focusing on rare respiratory diseases, has announced the grant of inducement awards to four new employees. The Compensation Committee of Savara's Board of Directors granted these awards on October 17, 2024, consisting of:
- Options to purchase 95,000 shares of common stock
- Restricted stock units (RSUs) covering 95,000 shares of common stock
These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan, in compliance with NASDAQ Listing Rules. The options have an exercise price of $3.65 per share, a 10-year term, and vest quarterly over four years. The RSUs vest in full after two years, subject to continued employment.
Savara, a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of an abstract for poster presentation at the CHEST 2024 Annual Meeting, scheduled for October 6-9 in Boston. The abstract, titled “A Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP),” will be featured in the Diffuse Lung Disease Abstracts Posters (D) session on October 8, 2024, from 1:45 to 2:30pm EDT. Additionally, Savara is sponsoring an Industry Symposium at the meeting, titled “Pulmonary Alveolar Proteinosis: Pathophysiology, Diagnosis, and Management,” which will take place on October 8, 2024, from 2:00 to 2:45pm EDT at the CHEST Learning Theater. The symposium will be led by Dr. Ali Ataya, Associate Professor of Medicine at the University of Florida, Division of Pulmonary and Critical Care Medicine.
FAQ
What is the current stock price of Savara (SVRA)?
What is the market cap of Savara (SVRA)?
What does Savara Inc. specialize in?
What is AeroVanc?
What is molgramostim?
What is autoimmune pulmonary alveolar proteinosis (aPAP)?
Where can I find more information about Savara Inc.?
How is Savara Inc. funded?
What is the main focus of Savara's development pipeline?
Is AeroVanc currently available on the market?
What stage is molgramostim in?
Does Savara Inc. have any other products in development?
